KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to $1.7 billion.

  • Abbott Laboratories' Accumulated Expenses rose 723.11% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 723.11%. This contributed to the annual value of $1.7 billion for FY2024, which is 651.22% up from last year.
  • Abbott Laboratories' Accumulated Expenses amounted to $1.7 billion in Q3 2025, which was up 723.11% from $1.6 billion recorded in Q2 2025.
  • Abbott Laboratories' Accumulated Expenses' 5-year high stood at $1.7 billion during Q3 2025, with a 5-year trough of $1.1 billion in Q1 2024.
  • In the last 5 years, Abbott Laboratories' Accumulated Expenses had a median value of $1.4 billion in 2022 and averaged $1.4 billion.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 1770.28% in 2021, then crashed by 427.2% in 2023.
  • Abbott Laboratories' Accumulated Expenses (Quarter) stood at $1.6 billion in 2021, then decreased by 4.25% to $1.6 billion in 2022, then grew by 2.63% to $1.6 billion in 2023, then increased by 6.51% to $1.7 billion in 2024, then rose by 2.0% to $1.7 billion in 2025.
  • Its Accumulated Expenses stands at $1.7 billion for Q3 2025, versus $1.6 billion for Q2 2025 and $1.2 billion for Q1 2025.